PepGen Inc
PEPG5.317USD
-0.123-2.25%
Market hours （ET）Quotes delayed by 15 min
365.56MMarket Cap
LossP/E TTM
More Details of PepGen Inc Company
PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
PepGen Inc Info
Ticker SymbolPEPG
Company namePepGen Inc
IPO dateMay 06, 2022
CEOMcArthur (James G)
Number of employees81
Security typeOrdinary Share
Fiscal year-endMay 06
Address245 Main St, 2nd Floor
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone17034568000
Websitehttps://pepgen.com
Ticker SymbolPEPG
IPO dateMay 06, 2022
CEOMcArthur (James G)
Company Executives of PepGen Inc
Name
Name/Position
Position
Shareholding
Change
Dr. James G. Mcarthur, Ph.D.
Dr. James G. Mcarthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.19K
+3040.14%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.17K
--
Ms. Mary Beth Delena, J.D.
Ms. Mary Beth Delena, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
1.43K
-8.67%
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Dr. Paul D. Streck, M.D.
Dr. Paul D. Streck, M.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
--
--
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Dr. Howard Mayer, M.D.
Dr. Howard Mayer, M.D.
Independent Director
Independent Director
--
--
Dr. Kasra Kasraian, Ph.D.
Dr. Kasra Kasraian, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. James G. Mcarthur, Ph.D.
Dr. James G. Mcarthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.19K
+3040.14%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.17K
--
Ms. Mary Beth Delena, J.D.
Ms. Mary Beth Delena, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
1.43K
-8.67%
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Dr. Paul D. Streck, M.D.
Dr. Paul D. Streck, M.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
29.19%
Oxford Science Enterprises PLC
7.21%
Viking Global Investors LP
5.07%
Commodore Capital LP
3.43%
Vivo Capital, LLC
3.38%
Other
51.73%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
29.19%
Oxford Science Enterprises PLC
7.21%
Viking Global Investors LP
5.07%
Commodore Capital LP
3.43%
Vivo Capital, LLC
3.38%
Other
51.73%
Shareholder Types
Shareholders
Proportion
Venture Capital
40.87%
Hedge Fund
24.67%
Investment Advisor/Hedge Fund
14.63%
Investment Advisor
7.70%
Sovereign Wealth Fund
1.81%
Private Equity
1.21%
Research Firm
0.85%
Individual Investor
0.18%
Other
8.09%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
157
41.73M
60.71%
+1.86M
2025Q2
165
31.28M
95.59%
-5.47M
2025Q1
168
31.44M
96.09%
-5.26M
2024Q4
160
31.09M
95.12%
-3.10M
2024Q3
156
31.41M
96.35%
-1.62M
2024Q2
150
31.22M
97.59%
-974.84K
2024Q1
140
30.76M
96.24%
+4.98M
2023Q4
127
22.26M
93.52%
+3.25M
2023Q3
124
22.70M
95.37%
+3.35M
2023Q2
119
23.17M
97.35%
+3.81M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
20.06M
29.19%
+9.38M
+87.70%
Sep 26, 2025
Oxford Science Enterprises PLC
4.96M
7.21%
+200.00K
+4.21%
Sep 30, 2025
Viking Global Investors LP
3.48M
5.07%
+2.00M
+134.91%
Sep 26, 2025
Point72 Asset Management, L.P.
2.76M
4.01%
+83.23K
+3.11%
Jun 30, 2025
Laurion Capital Management LP
810.76K
1.18%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
937.02K
1.36%
+37.29K
+4.14%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Micro-Cap ETF
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.01%
Proshares Ultra Russell 2000
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
View more
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
iShares Micro-Cap ETF
Proportion0.02%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of PepGen Inc?
The top five shareholders of PepGen Inc are:
RA Capital Management, LP holds 20.06M shares, accounting for 29.19% of the total shares.
Oxford Science Enterprises PLC holds 4.96M shares, accounting for 7.21% of the total shares.
Viking Global Investors LP holds 3.48M shares, accounting for 5.07% of the total shares.
Point72 Asset Management, L.P. holds 2.76M shares, accounting for 4.01% of the total shares.
Laurion Capital Management LP holds 810.76K shares, accounting for 1.18% of the total shares.
RA Capital Management, LP holds 20.06M shares, accounting for 29.19% of the total shares.
Oxford Science Enterprises PLC holds 4.96M shares, accounting for 7.21% of the total shares.
Viking Global Investors LP holds 3.48M shares, accounting for 5.07% of the total shares.
Point72 Asset Management, L.P. holds 2.76M shares, accounting for 4.01% of the total shares.
Laurion Capital Management LP holds 810.76K shares, accounting for 1.18% of the total shares.
What are the top three shareholder types of PepGen Inc?
The top three shareholder types of PepGen Inc are:
RA Capital Management, LP
Oxford Science Enterprises PLC
Viking Global Investors LP
RA Capital Management, LP
Oxford Science Enterprises PLC
Viking Global Investors LP
How many institutions hold shares of PepGen Inc (PEPG)?
As of 2025Q3, 157 institutions hold shares of PepGen Inc, with a combined market value of approximately 41.73M, accounting for 60.71% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -34.88%.
What is the biggest source of revenue for PepGen Inc?
In --, the -- business generated the highest revenue for PepGen Inc, amounting to -- and accounting for --% of total revenue.
